ProMIS Neurosciences Reports New Milestones in Potential Therapeutic Approaches for Amyotrophic Lateral Sclerosis (ALS)
28. April 2022 07:00 ET
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, MA, April 28, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of...
ProMIS appoints experienced industry veteran Larry Altstiel as Chief Medical Officer
19. April 2022 07:00 ET
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of...
ProMIS Files Management Information Circular in Connection with Annual General and Special Meeting of Shareholders
07. April 2022 07:00 ET
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Massachusetts, April 07, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Corporation”), is pleased to announce it has...
ProMIS Neurosciences Presents at the 2022 American Academy of Neurology Annual Meeting
07. April 2022 07:00 ET
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, MA, April 07, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of...
ProMIS Neurosciences to Present at the 10th Annual Neurodegenerative Drug Development Summit
24. März 2022 07:00 ET
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, MA , March 24, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of...
ProMIS Neurosciences Presents Preclinical Results of its Experimental Alzheimer’s Vaccine at the 2022 International AD/PDTM Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
22. März 2022 07:00 ET
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of...
ProMIS Neurosciences Announces Fiscal Year 2021 Results
17. März 2022 07:00 ET
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Massachusetts , March 17, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused...
ProMIS Neurosciences to Present at the 2022 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PDTM) and Related Neurological Disorders
10. März 2022 07:00 ET
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of...
ProMIS Neurosciences’ PMN310 antibody demonstrates significant cognitive benefit in a mouse model of Alzheimer’s disease
02. März 2022 07:00 ET
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of...
ProMIS Neurosciences Appoints Renowned Neuroscientists, Dr. Guy Rouleau and Dr. Alain Dagher to its Scientific Advisory Board
03. Februar 2022 07:00 ET
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Mass. , Feb. 03, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of...